. 2021 Feb;10(2):737–752. doi: 10.21037/tlcr-20-958

Table 4. Univariate and multivariate Cox proportional hazard regression analysis for PFS and OS.

Variable	Univariate analysis (PFS)			Multivariate analysis (PFS)			Univariate analysis (OS)			Multivariate analysis (OS)
Variable	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value	HR	95% CI	P value
Age
<70 vs. ≥70 years	1.09	0.72–1.64	0.70				0.79	0.48–1.31	0.37
Sex
Female vs. male	1.08	0.71–1.64	0.72				0.94	0.56–1.56	0.80
ECOG-PS
0–1 vs. ≥2	0.71	0.43–1.17	0.18				0.43	0.25–0.74	0.003*	0.40	0.23–0.71	0.002*
Smoking history
Current or former vs. never smoker	0.36	0.18–0.72	0.004*	0.43^a	0.21–0.89	0.02*	0.45	0.19–1.06	0.07
				0.49^b	0.24–1.01	0.05*
				0.43^c	0.21–0.89	0.02*
Histology
Adenocarcinoma (LuAD) vs. other	1.14	0.68–1.91	0.62				0.82	0.46–1.46	0.50
PD–L1 expression (%TC)
<70 vs. ≥70%	1.72	1.14–2.60	0.01*	1.41^a	0.90–2.21	0.13	1.93	1.16–3.20	0.01*	1.65	0.98–2.76	0.06
				1.51^b	0.97–2.35	0.07
				1.40^c	0.90–2.19	0.13
Molecular alteration
KRAS (pos. vs. neg.)	0.66	0.44–1.00	0.05*	0.75	0.48–1.18	0.13	0.92	0.55–1.52	0.73
KRAS^G12C (pos. vs. KRAS^other/KRAS^wt)	0.41	0.24–0.69	0.001*	0.42	0.24–0.73	0.002*	0.58	0.32–1.08	0.08
KRAS^G12C/TP53^mut (pos. vs. else)	0.30	0.12–0.74	0.009*	0.32	0.13–0.80	0.02*	0.23	0.06–0.93	0.04*	0.20	0.05–0.82	0.03*
TP53 (pos. vs. neg.)	0.97	0.64–1.46	0.88				0.85	0.51–1.41	0.52
Stage at primary diagnosis
III vs. IV	1.09	0.63–1.90	0.76				0.78	0.37–1.65	0.78
Metastatic sites at the begin of IO, n (%)
ADR (Y vs. N)	1.26	0.74–2.14	0.39				1.34	0.71–2.51	0.37
BRA (Y vs. N)	1.00	0.60–1.66	1.00				1.10	0.60–2.04	0.76
HEP (Y vs. N)	0.75	0.36–1.55	0.44				0.82	0.33–2.06	0.67
OSS (Y vs. N)	0.88	0.55–1.40	0.58				0.97	0.56–1.71	0.92

*, P<0.05; ^a, HR for KRAS (pos. vs. neg.); ^b, HR for KRAS^G12C (pos. vs. KRAS^else/KRAS^wt); ^c, HR for KRAS^G12C/TP53^mut (pos. vs. else); CI, confidence interval; ECOG-PS, Eastern Co-operative Oncology Group Performance Status; %TC, percentage of positive tumor cells; ADR, adrenal metastases; BRA, brain metastases; HEP, liver metastases; OSS, bone metastases.